ReviewZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2016
[Significance of HBsAg quantification in guiding clinical treatment of chronic hepatitis B].
Review in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 4 citations in OpenAlex.
- Clinical characteristics and association analysis of persistent low-level HBsAg expression in a physical examination population with HBV infection.Experimental and therapeutic medicine · 2020Article
- An epidemiological survey of HBV infection and low-level HBsAg in military camps in eastern China.Medicine · 2018Observational
- Clinical Characteristics and Correlation Analysis of Subjects with Chronic Hepatitis B Virus (HBV) Infection and Sustained Low Levels of Hepatitis B Surface Antigen (HBsAg).Medical science monitor : international medical journal of experimental and clinical research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Serum hepatitis B surface antigen (HBsAg) quantification can reflect the level of HBV replication and can be used as a surrogate maker for the evaluation of infected cells. Recent studies have shown that HBsAg quantification can help to distinguish the nature history of chronic hepatitis B and predict spontaneous clearance of HBsAg and the risk of progressive liver diseases. The dynamic change in HBsAg helps to predict the therapeutic effects of interferon and nucleoside analogues and sustained virologic response, guide withdrawal, and improve and optimize the therapeutic strategy for chronic hepatitis B in clinical practice. These issues have become the hot topics in recent years. However, the cut-off values of HBsAg level in patient management and various therapeutic strategies have not been determined. This article reviews the research advances in the significance of HBsAg quantification in the natural history and optimized treatment of chronic hepatitis B.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.